Pfizer (PFE) stock is a new Buy at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Guggenheim Starts Pfizer (PFE) at Buy, 'Successful Execution Can Drive Upside'
February 22, 2024 4:10 PM EST(Updated - February 23, 2024 4:04 AM EST)
Guggenheim analyst Vamil Divan initiates coverage on Pfizer (NYSE: PFE) with a Buy rating and a price target of $36.00.
The analyst comments "We are initiating coverage on Pfizer Inc. (PFE) with a BUY rating and $36 price target. Pfizer shares have significantly underperformed... More
